Former WH Covid Czar slams RFK Jr.'s firing of vaccine advisory panel
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Is it a Great Time to Invest in Danaher Corp. (DHR)?
Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79% for the same period. The fund's top 5 holdings are also listed in the letter, showing the firm's main investment positions heading into 2025. One of the companies mentioned in the letter is Danaher Corporation (NYSE:DHR). Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. Over the past month, Danaher Corporation (NYSE:DHR) rose by 7.69%, and its shares lost -23.01% of their value over the last 12 months. On August 12, 2025, Danaher Corporation (NYSE:DHR) shares closed at $205.72, with a market capitalization of $147.3 billion. Here is what they have to say about Danaher Corporation (NYSE:DHR) in their investor letter: "Danaher Corporation's (NYSE:DHR) valuation is attractive, considering its scale advantages and deeply embedded products in biopharma workflows, which are difficult to replace without regulatory reapproval. Additionally, the company's market dominance positions it well to benefit from secular growth trends in biologics, genetic medicine and diagnostics. Although the industry faces near-term demand, policy and tariff challenges, we believe these factors have been largely reflected in the valuation." A healthcare professional in a lab coat holding a microscope and looking at a slide under the Danaher Corporation (NYSE:DHR) ranks 27th in our list of the 30 most popular stocks among hedge funds. According to our data, 117 hedge fund portfolios held positions in Danaher Corporation (NYSE:DHR) at the end of the first quarter of 2025, up from 101 in the previous quarter. DHR was able to beat earnings expectations as it reported an EPS of $1.8, beating expectations of $1.64. While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Danaher Corporation (NYSE:DHR) and Jim Cramer's views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Hims & Hers (HIMS) Falls as Key Executives Dispose Shares
We recently published Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing stocks on Tuesday. Shares of telehealth company Hims & Hers Health dropped by 4.04 percent on Tuesday as investors mirrored a selloff from key executives of the company, which included none other than its CEO. In a regulatory filing, Hims & Hers Health, Inc. (NYSE:HIMS) said its CEO, Andrew Dudum, sold $33.4 million of shares in the company, involving 660,000 units at a price of $50.58 apiece. The transaction was aimed at cashing in on gains from the stock's recent rally. Despite the sale, Dudum remains the largest individual shareholder, owning 8 million indirect shares and 92,313 direct holdings in Hims & Hers Health, Inc. (NYSE:HIMS). Meanwhile, other key executives also resorted to profit-taking in the past trading days. In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while Chief Medical Officer Patrick Carroll disposed of 60,000 shares for a total of $3.2 million. Copyright: wasansos1 / 123RF Stock Photo Since the start of the month, shares of Hims & Hers Health, Inc. (NYSE:HIMS) have already dropped by 27.5 percent. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Cardinal Health (CAH) Falls on Dismal Revenue Performance
We recently published Cardinal Health, Inc. (NYSE:CAH) is one of the worst-performing stocks on Tuesday. Cardinal Health dropped its share prices by 7.21 percent on Tuesday to finish at $146.3 apiece as investors soured on its dismal revenue performance in both the fourth quarter and the full fiscal period of 2025. In its updated report, Cardinal Health, Inc. (NYSE:CAH) said revenues in the fourth quarter of the year finished flat at $60 billion, but attributable net income grew by 11 percent to $501 million from $450 million in the same period last year. In the full fiscal year of 2025, revenues decreased by 2 percent to $222.6 billion from $226.8 billion last year. Attributable net income, however, grew by 7 percent to $2 billion from $1.9 billion year-on-year. In other news, Cardinal Health, Inc. (NYSE:CAH) announced the acquisition of Solaris Health through its management services organization (MSO), The Specialty Alliance. A dose bottle of the medication is in the medical tech's hand Under the transaction, Cardinal Health, Inc. (NYSE:CAH) will infuse $1.9 billion in cash into The Specialty Alliance, in turn, raising its ownership in the latter to approximately 75 percent. Cardinal Health said it expects the transaction to close by the end of the year, subject to closing conditions, including the receipt of required physician and regulatory approvals. While we acknowledge the potential of CAH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
